Education
About Us
Working with TipRanks
Follow Us
NeurAxis, Inc. (NRXS)
:NRXS
Earnings Data
Report Date
May 21, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
―Last Year’s EPS
-0.32Same Quarter Last Year
Based on 0 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Mar 20, 2025
|% Change Since: -6.11%
|Next Earnings Date:May 21, 2025
Earnings Call Sentiment|Positive
The call highlighted significant growth in revenue and insurance coverage, the awarding of a Category 1 CPT code, and successful FDA clearances, indicating positive momentum. However, financial losses and ongoing challenges with insurance coverage and expenses present ongoing concerns.Company Guidance
During NeurAxis' fourth quarter 2024 earnings call, the company provided robust guidance, highlighting a range of metrics and milestones that underscore their growth trajectory. NeurAxis reported significant revenue growth of 43% in Q4 2024, following a 40% increase in Q3, attributed to the expansion of covered lives from 4 million to 51 million. The company is optimistic about further revenue acceleration with the upcoming effective date of the Category 1 CPT code on January 1, 2026, which will streamline billing and reimbursement processes. Additionally, NeurAxis expanded the age indication for their IB-Stim technology from 11-18 years to 8-21 years, nearly doubling their market opportunity. The company also received FDA clearance for their RED device, aimed at improving diagnostic accuracy for pelvic floor dysfunction. These advancements, along with strong gross margins of 86.4% in Q4 and strategic efforts to increase insurance coverage, position NeurAxis to achieve cash flow breakeven at an estimated revenue range of $10 million to $12 million.Significant Revenue Growth
Revenue grew by 43% in Q4 2024 compared to Q4 2023, reaching $761,000. The company also recorded a 45% increase in unit sales.
Expansion of Covered Lives
Covered lives increased from 4 million to approximately 51 million, indicating significant progress in insurance coverage.
Category 1 CPT Code Awarded
The American Medical Association awarded a Category 1 CPT code, effective January 1, 2026, which is expected to streamline billing and reimbursement processes.
FDA Clearance and Product Launch
Received FDA clearance for the rectal expulsion device (RED) on December 6 and began commercialization, with the first order booked in Q1 2025.
Gross Margins Maintained
Despite increased discounts, gross margins were maintained at 86.4% in Q4 2024, the same as Q4 2023.
Successful Age Expansion for IB-Stim
The FDA expanded the age range for IB-Stim from 11-18 years to 8-21 years, significantly increasing the market opportunity.
---
NRXS Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
NRXS Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Mar 20, 2025 | $2.29 | $2.27 | -0.87% |
| Nov 12, 2024 | $2.50 | $3.16 | +26.40% |
| Aug 09, 2024 | $2.85 | $3.11 | +9.12% |
| May 22, 2024 | $3.05 | $2.91 | -4.59% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does NeurAxis, Inc. (NRXS) report earnings?
NeurAxis, Inc. (NRXS) is schdueled to report earning on May 21, 2025, TBA Not Confirmed.
What is NeurAxis, Inc. (NRXS) earnings time?
NeurAxis, Inc. (NRXS) earnings time is at May 21, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is NRXS EPS forecast?
Currently, no data Available
---